EN DE
STOCK COMPARISON

Medicamen Biotech vs Jiangsu Hengrui Medicine Co: Fair Value & Quality

Both stocks run through our valuation models. Here is how Medicamen Biotech (MEDICAMEQ) and Jiangsu Hengrui Medicine Co (600276) compare, as of Aug 18, 2026.

As of Aug 18, 2026, Fair Value Calculator sees Medicamen Biotech as the less overvalued of the two: Medicamen Biotech trades at ₹220 versus a fair value of ₹131 (-40%), while Jiangsu Hengrui Medicine Co trades at ¥52.87 versus ¥25.94 (-51%).
Medicamen Biotech
MEDICAMEQ.NSE · INR · Health Care
-40%
upside to fair value
overvalued
Price₹220
Fair Value₹131
Quality41/100
Jiangsu Hengrui Medicine Co
600276.SHG · CNY · Health Care
-51%
upside to fair value
overvalued
Price¥52.87
Fair Value¥25.94
Quality66/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Medicamen BiotechJiangsu Hengrui Medicine Co
Valuation
30.5×P/E (TTM)43.6×
1.73×P/S (TTM)10.84×
1.26×P/B5.76×
14.2×EV/EBITDA33.0×
PEG0.93×
0.4%Dividend yield0.4%
₹1.00Dividend per share¥0.20
Profitability
5%Net margin25%
9%Operating margin32%
4%Return on equity15%
3%Return on assets9%
Growth
80%Revenue growth (YoY)13%
12.0%Avg. growth/yr (3Y)13.9%
11.9%Avg. growth/yr (5Y)2.5%
Balance & size
0.02×Debt / equity
$37MMarket cap$52B
expensiveGrowth qualityhealthy

Medicamen Biotech leads: 7 to 5 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Medicamen Biotechof which business quality 41 · market factors 23 Jiangsu Hengrui Medicine Coof which business quality 68 · market factors 43
ProfitabilityMargins and returns on capital today
29
63
Quality GrowthAre margins and returns improving?
58
41
CashflowEarnings quality: real cash, not paper profit
0
82
Fin. StrengthBalance sheet, leverage, solvency risk
69
100
InvestmentDisciplined investing over empire-building
62
27
Low VolatilityCalm price path (market factor)
63
79
MomentumPrice trend over the last 3–12 months (market factor)
9
33
52W MomentumDistance to the 52-week high (market factor)
2
21
Net IssuanceBuybacks instead of dilution
44
64

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Medicamen Biotech

DCF Models₹181
Earnings-Based₹79.09
Dividend Discount₹16.31
Multiples₹147
Asset-Based₹136
Economic Profit₹120
Growth Earnings₹117

16 of 17 models see the stock below the current price.

Jiangsu Hengrui Medicine Co

DCF Models¥37.78
Earnings-Based¥21.29
Dividend Discount¥3.82
Multiples¥23.65
Asset-Based¥6.44
Growth DCF¥39.88
Economic Profit¥18.21
Growth Earnings¥30.99

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Medicamen Biotech
Bear ₹104Fair Value ₹131Bull ₹131
₹220 = current price (white tick)
Jiangsu Hengrui Medicine Co
Bear ¥19.95Fair Value ¥25.94Bull ¥32.81
¥52.87 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Medicamen Biotech · Health Care

Quality score41 · below median
Fair value upside-40% · below median

Jiangsu Hengrui Medicine Co · Health Care

Quality score66 · Top 25%
Fair value upside-51% · below median

Bottom line

As of Aug 18, 2026, Fair Value Calculator sees Medicamen Biotech as the less overvalued of the two: Medicamen Biotech trades at ₹220 versus a fair value of ₹131 (-40%), while Jiangsu Hengrui Medicine Co trades at ¥52.87 versus ¥25.94 (-51%).

Jiangsu Hengrui Medicine Co has the higher quality score (66/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.